CIO Dive

NIST adds to AI security guidance with Cybersecurity Framework profile

Multiple presidents have tasked NIST with developing security guidance for AI. President Joe Biden ordered NIST to publish ...
TMCnet

Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy

The FLAMINGO-01 DSMB met twice in 2025, most recently in December 2025, and recommended to continue the study as is without modification. The Steering Committee also met at SABCS 2025 and discussed ...
Le Lézard

Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*

Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the EPO notified the Company of its intention to grant a patent application ...

Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01 ...
Targeted Oncology

Sacituzumab Govitecan Safety: Manageable AEs in First-Line TNBC Therapy

Sacituzumab govitecan showed lower rates of dose reductions and treatment discontinuations due to adverse effects compared to chemotherapy in TNBC patients. Common adverse effects, such as diarrhea ...

(PMZN) Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01

-- 80% or greater reduction in metastatic breast cancer recurrence rate over 5 years of follow-up with a peak immune response at 6 months and well-tolerated safety profile. -- The PIS elicited a ...

Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01

A preliminary analysis of recurrence rates by two methods to estimate the reduction in recurrence rate shows an approximately 80% reduction in recurrence rate in the fully enrolled, 250 patient ...
The Manila Times

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet ...

Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs)demonstrate durable seizure reductions, including increases in seizure ...

Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01

Enhertu (trastuzumab Deruxtecan [T-DXd]) treated patients continue to be eligible for enrollment in FLAMINGO-01. The Company believes that GLSI-100 will synergize with any trastuzumab based treatment ...

Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease

Results showed CNS target engagement with reduction in GCase substrate glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF), a prespecified endpoint The reduction in GluSph in CSF, a first-ever ...
IGN

iPhone 14 vs iPhone 14 Pro Models: What are the Differences?

Apple has finally unveiled the new iPhone 14 and iPhone 14 Pro. The Apple cynical may think that there probably isn't a huge difference between them. Indeed, many components are the exact same between ...